The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review
Abstract
The catastrophic antiphospholipid syndrome (CAPS) is a life-threating variant of the antiphospholipid syndrome characterized by the development of multiple thrombosis in a short period of time, usually ending up in the failure of function of several vital organs. Most CAPS episodes are related to a prothrombotic situation or precipitating factor such as infections, surgical procedures or malignant diseases. In patients with CAPS, the development of multiple thrombosis leads to an important cytokine release that worsens the already critical patient's situation. The disease usually involves the kidneys, the lungs and the heart, although any organ system can be affected. Although occasionally the disease affects large vessels, in the majority of cases it affects small vessels, leading to a disseminated microangiopathic syndrome resembling thrombotic thrombocytopenic purpura. Treatment is based on the administration of anticoagulants, corticosteroids, plasma exchange and/or intravenous immunoglobulins. Cyclophosphamide is recommended in those CAPS cases associated to systemic lupus erythematosus. Additionally, rituximab and eculizumab have been used in refractory cases. Mortality is still around 30% despite current treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156
Adjunctive glucocorticoid therapy in patients with septic shock.
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705835 · Cited by 1,037
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., Berthelot, J.-M., Perdriger, A., Puéchal, X., Le Guern, V., Sibilia, J., Gottenberg, J.-E., Chiche, L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1085 · Cited by 429
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Current perspectives on severe drug eruption
Zhang, J., Lei, Z., Xu, C., Zhao, J., & Kang, X. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08859-0 · Cited by 60
Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome
Petri, M. (2019) · Hematology · doi:10.1182/hematology.2019000046 · Cited by 11
Metadata
- Authors
- Cervera, R., Rodríguez-Pintó, I., & Espinosa, G.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 92
- Pages
- 1-11
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2804160360
- Cited by
- 217
- References
- 6
- FWCI
- 17.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. https://app.cochat.ai/papers/10.1016/j.jaut.2018.05.007
- The paper
- Cervera, R., Rodríguez-Pintó, I., & Espinosa, G. (2018). The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2018.05.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
